[CAS NO. 2143452-20-2] TSHRantagonistS37a

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [2143452-20-2]

Catalog

HY-129995A

Brand

MCE

CAS

2143452-20-2

DESCRIPTION [2143452-20-2]

Overview

MDL	-
Molecular Weight	460.57
Molecular Formula	C25H20N2O3S2
SMILES	O=C(N1)SC([C@H]2C3=CC=CC=C3)=C1S[C@@]([C@@]2([H])[C@@]4([H])[C@@]56[H])([H])[C@](C4)([H])[C@]6([H])C(N(C7=CC=CC=C7)C5=O)=O

For research use only. We do not sell to patients.

Summary

TSHR antagonist S37a is a highly selective thyrotropin receptor (TSHR) antagonist, with potential for the treatment of Graves' orbitopathy ^[1] .

IC50 & Target

TSHR ^[1]

In Vitro

TSHR antagonist S37a exhibits inhibition activity for TSHR, with IC ₅₀ s of 40 µM and approximately 20 µM for mTSHR and hTSHR, respectively, in HEK293 cells ^[1] .
TSHR antagonist S37a not only inhibits the TSHR activation by thyrotropin itself but also activation by monoclonal TSAb M22 (human), KSAb1 (murine), and the allosteric small-molecule agonist C2 ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

TSHR antagonist S37a also inhibits cyclic adenosine monophosphate formation by oligoclonal TSAb, which are highly enriched in GO patients' sera ^[1] .
TSHR antagonist S37a (10 mg/kg ;i.g.) displays no toxicity and a remarkable 53% oral bioavailability in mice ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	SWISS (CD1) mice (38-43 g) ^[1]
Dosage:	10 mg/kg
Administration:	Oral gavage
Result:	Displays a remarkable 53% oral bioavailability as well as a half‐life of 2.9 hours after oral application.

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL ( 217.12 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.1712 mL	10.8561 mL	21.7122 mL
5 mM	0.4342 mL	2.1712 mL	4.3424 mL
10 mM	0.2171 mL	1.0856 mL	2.1712 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (5.43 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: 2.5 mg/mL (5.43 mM); Suspended solution; Need ultrasonic
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (5.43 mM); Clear solution

* All of the co-solvents are available by MCE.

References

[1] Marcinkowski P, et al. A New Highly Thyrotropin Receptor-Selective Small-Molecule Antagonist with Potential for the Treatment of Graves' Orbitopathy. Thyroid. 2019 Jan;29(1):111-123.